Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Special Drug Use-Results Survey of Velexbru in WM/LPL
jRCT2011210005Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tirabrutinib in Waldenström macroglobulinemia (WM) and Lymphoplasmacytic Lymphoma (LPL), sponsored by Ono Pharmaceutical. Primary endpoints: Occurrence of adverse drug reactions and infections, Occurrence of adverse drug reactions corresponding to specified safety concerns and 1 more. Started Sep 2020; status: completed.
02
Drugs
tirabrutinib
03
Conditions
Waldenström macroglobulinemia (WM)Lymphoplasmacytic Lymphoma (LPL)
Beyond the preview
Go deeper on jRCT2011210005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011210005.